TerminatedNot Applicable

A Pharmacist-run PrEP Program for Women

Stopped: This protocol was early terminated on 10/15/2024 due to low enrollment

United States2 participantsStarted 2023-06-21

Plain-language summary

The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also include reasons for lack of retention in PrEP care)

Who can participate

Age range18 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Partner living with HIV with unknown viral load
✓. ≥1 sex partner of unknown HIV status
✓. Bacterial STI in the past 6 months (GC/Chlamydia or syphilis)

Exclusion criteria

✕Evidence of Hepatitis C virus (HCV) infection based on the results of testing at Screening for Hepatitis C antibody (HCV Ab) and HCV RNA as follows:

What they're measuring

Uptake of LA-CAB vs. TDF/FTC for PrEP

Timeframe: 48 weeks

Persistence on LA-CAB vs. TDF/FTC for PrEP

Timeframe: 48 weeks

Trial details

NCT IDNCT05755204

SponsorOrlando Immunology Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-15

View on ClinicalTrials.gov More HIV Prevention trials